The business case for cell and gene therapies

Nat Biotechnol. 2014 Dec;32(12):1192-3. doi: 10.1038/nbt.3084.

Authors

Mohamed Abou-El-Enein¹, Gerhard Bauer², Petra Reinke¹

Affiliations

¹ 1] Berlin-Brandenburg Center for Regenerative Therapies, Charité University Medicine, Campus Virchow, Berlin, Germany. [2] Department of Nephrology and Internal Intensive Care, Charité University Medicine, Campus Virchow, Berlin, Germany.
² University of California, Davis, Institute For Regenerative Cures, Sacramento, California, USA.

PMID: 25489833
DOI: 10.1038/nbt.3084

No abstract available

Publication types

Letter

MeSH terms

Cell- and Tissue-Based Therapy / economics*
Cost-Benefit Analysis
Genetic Therapy / economics*
Humans